

demonstrated their capacity for procurement, distribution and tracking of health-related commodities to government health facilities over the past 12 months through the essential drugs pull system. Because program implementation is to begin in September 2004 it is necessary to work with an organization already providing supplies to the government health sector. NMS will in addition work with the Joint Medical Stores (JMS) to ensure that NGO and faith-based health facilities have access to laboratory supplies through an integrated logistics system. The logistics system will have the capacity to absorb donations from donors other than CDC, either as cash or product, and to distribute and track these supplies; examples are the HIV test kits procured by MAP funding and the laboratory supplies purchased and distributed by the TB and malaria control programs.

NMS is based in Entebbe and has good warehousing facilities and well-developed systems for procurement, storage, stock control and distribution. It is expected that the existing facilities and systems will absorb the increased level of activities resulting from implementation of the laboratory logistics system though inevitably some increase in capacity will be needed. Vehicles, which currently deliver essential drug kits around the country, will, in addition, carry the laboratory supplies pre-packaged for each health unit.

C. Funding

Approximately \$1,000,000 is available in FY 2004 to fund this award. It is expected that the award will begin on or before September 1, 2004, and will be made for a 12-month budget period within a project period of up to 5 years. Funding estimates may change.

D. Where To Obtain Additional Information

For general comments or questions about this announcement, contact: Technical Information Management, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone: 770-488-2700.

For technical questions about this program, contact: Jonathan Mermin, MD, MPH, Global Aids Program [GAP], Uganda Country Team, National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention [CDC], PO Box 49, Entebbe,

Uganda. Telephone: +256-41320776. E-mail: jhm@cdc.gov.

William P. Nichols,

MPA, Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04-18101 Filed 8-6-04; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 05004]

Comprehensive STD Prevention Systems, Prevention of STD-Related Infertility, and Syphilis Elimination—Amendment

A notice announcing the availability of fiscal year (FY) 2005 funds for Comprehensive STD Prevention Systems, Prevention of STD-Related Infertility, and Syphilis Elimination was published in the **Federal Register** on July 21, 2004, Volume 69, Number 139, pages 43595-43607. The notice is amended as follows:

- Page 43604, second column, CSPS number 2—Sentence should read, “When federal funds are used to develop or purchase STD health education materials, they shall contain medically accurate information regarding the effectiveness or lack of effectiveness of condoms in preventing the STD the materials are designed to address.
- Page 43605, first and second columns, V. Application Review Criteria—Please delete and disregard the review criteria listed for QEI and GISP; these scoring systems do not apply, as all applications will undergo technical acceptability reviews (TAR).
- Page 43605, second column, V.2. Review and Selection Process, second paragraph—Please replace “objective review panel” with “technical acceptability review group”.
- Page 43607, first column, VI.3. Reporting Requirements, numbers 2 and 3 will become numbers 3 and 4. Please insert the following language as reporting requirement number 2, “Annual progress report, due March 31 following the end of each budget period. Include the following items: reporting budget period activities and objectives; Tables 1 through 3, previously listed for the interim progress report; and measures of effectiveness, also previously listed for the interim progress report.

Dated: August 3, 2004.

William P. Nichols,

Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention.

[FR Doc. 04-18109 Filed 8-6-04; 8:45 am]

BILLING CODE 4163-18-U

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Statement of Organization, Functions, and Delegations of Authority

Part C (Centers for Disease Control and Prevention) of the Statement of Organization, Functions, and Delegations of Authority of the Department of Health and Human Services (45 FR 67772-76, dated October 14, 1980, and corrected at 45 FR 69296, October 20, 1980, as amended most recently at 69 FR 17166-17167, dated April 1, 2004) is amended to reorganize the Division of Parasitic Diseases, National Center for Infectious Diseases.

Section C-B, Organization and Functions, is hereby amended as follows:

Delete in its entirety the functional statement for the *Division of Parasitic Diseases (CRS)* and insert the following: *Division of Parasitic Diseases (CRS)*.

(1) Conducts surveillance, investigations, and studies of parasitic diseases to define disease etiology, mode of transmission, and populations at risk and to develop effective methods for diagnosis, prevention, control, and elimination; (2) conducts or participates in clinical, field, and laboratory research to develop, evaluate, and improve laboratory methodologies and materials and therapeutic practices used for rapid and accurate diagnosis and treatment of parasitic diseases; (3) provides epidemic aid and epidemiologic consultation, upon request, to State and local health departments, other Federal agencies, and national and international health organizations; (4) provides reference/diagnostic services for parasitic diseases to State and local health departments, other Federal agencies, and national and international health organizations; (5) conducts a program of research and development in the biology, ecology, host-parasitic relationships, and control of parasitic diseases; (6) conducts laboratory studies of selected parasitic infections, emphasizing animal models and in vitro systems for parasitic relationships, chemotherapy, and immunology, to develop effective methods for diagnosis, prevention, and